Immuneering Corp 10-K

Item 5. Market For The Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities Market Information for Common Stock Our common stock trades under the symbol “IMRX” on the Nasdaq Global Market. Holders of Our Common Stock As of February 27, 2023, there were approximately 60 registered holders of record of our common stock. The actual number of holders of our common stock is greater than this number of record holders and includes stockholders who are 108 Table of Contents beneficial owners, but whose shares are held in “street name” by brokers or held by other “nominees”. The number of holders of record also does not include stockholders whose shares may be held in trust by other entities. Dividend Policy We have never declared or paid any cash dividends on our common shares. We currently anticipate that we will retain all available funds and future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. Securities Authorized for Issuance Under Equity Compensation Plans See Item 12, Part III of this Form 10-K. Unregistered Sales of Equity Securities During the period covered by this Annual Report on Form 10-K, we did not issue any securities which were unregistered under the Securities Act and required to be disclosed herein. Issuer Purchases of Equity Securities We did not purchase any of our registered equity securities during the quarterly period ended December 31, 2022. ​ Item 6. [Reserved] ​